CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. More Details
Excellent balance sheet with limited growth.
Share Price & News
How has CRISPR Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRSP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CRSP's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CRSP exceeded the US Biotechs industry which returned 26.8% over the past year.
Return vs Market: CRSP exceeded the US Market which returned 53.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is CRISPR Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHow Many CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Do Institutions Own?
2 months ago | Simply Wall StInvestors Who Bought CRISPR Therapeutics (NASDAQ:CRSP) Shares Three Years Ago Are Now Up 411%
3 months ago | Simply Wall StNeed To Know: Analysts Are Much More Bullish On CRISPR Therapeutics AG (NASDAQ:CRSP) Revenues
Is CRISPR Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CRSP ($120.88) is trading above our estimate of fair value ($56.51)
Significantly Below Fair Value: CRSP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CRSP is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CRSP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CRSP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CRSP is overvalued based on its PB Ratio (5.4x) compared to the US Biotechs industry average (3.7x).
How is CRISPR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRSP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRSP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRSP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRSP's revenue (59.8% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: CRSP's revenue (59.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CRSP's Return on Equity is forecast to be high in 3 years time
How has CRISPR Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRSP is currently unprofitable.
Growing Profit Margin: CRSP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CRSP is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.
Accelerating Growth: Unable to compare CRSP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRSP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: CRSP has a negative Return on Equity (-20.96%), as it is currently unprofitable.
How is CRISPR Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CRSP's short term assets ($1.7B) exceed its short term liabilities ($94.3M).
Long Term Liabilities: CRSP's short term assets ($1.7B) exceed its long term liabilities ($69.5M).
Debt to Equity History and Analysis
Debt Level: CRSP is debt free.
Reducing Debt: CRSP has no debt compared to 5 years ago when its debt to equity ratio was 102.5%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRSP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CRSP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRSP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRSP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRSP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRSP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sam Kulkarni (41 yo)
Dr. Samarth Kulkarni, also known as Sam, Ph.D., has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as a Director of Centessa Pharmaceuticals Limited since...
CEO Compensation Analysis
Compensation vs Market: Sam's total compensation ($USD16.27M) is above average for companies of similar size in the US market ($USD6.39M).
Compensation vs Earnings: Sam's compensation has increased whilst the company is unprofitable.
Experienced Management: CRSP's management team is considered experienced (3.4 years average tenure).
Experienced Board: CRSP's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.2%.
CRISPR Therapeutics AG's company bio, employee growth, exchange listings and data sources
- Name: CRISPR Therapeutics AG
- Ticker: CRSP
- Exchange: NasdaqGM
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$8.649b
- Shares outstanding: 75.61m
- Website: https://www.crisprtx.com
Number of Employees
- CRISPR Therapeutics AG
- Baarerstrasse 14
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/13 22:11|
|End of Day Share Price||2021/04/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.